Riskpilot← Back to searchSign inGet full accessImplantbionics Ab
OYDissolvedY-tunnus 2228884-2C/O Lindholm Fyrvaktarvägen 2-BDental practice care activities · NACE 8623Est. 20082 employees
Revenue 2024
EUR 330K
-23% vs 2023
EBITDA margin
8.6%
-64% vs 2023
Equity ratio
98.8%
Financial strength
Net profit 2024
EUR 28K
-42% vs 2023
| Revenue | EUR 330K | -23% |
| EBITDA | EUR 28K | -64% |
| Net profit | EUR 28K | -42% |
| Total assets | EUR 844K | -5% |
| Equity | EUR 835K | -5% |
| Employees | 2 | — |
Legal name
Implantbionics Ab
Y-tunnus number
2228884-2
Legal form
Osakeyhtiö
NACE code
8623 · Dental practice care activities
Founded
27. lokakuuta 2008
Share capital
EUR 5 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin
Company purpose
Bolagets verksamhetsområde är tandvårdstjänster, oral och käkkirurgiska tjänster, medicinsk och odontologisk konsultverksamhet, skolning och utbildningsarrangemang. Köp, försäljning och uthyrning av aktier. Oral- och käkkirurgisk forskning och utvecklingsarbete.
Address
C/O Lindholm Fyrvaktarvägen 2-B
Phone
+3580505470860
Email
tclindholm@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 525 | 453 | 493 | 426 | 330 |
| Staff expenses | −124 | −134 | −142 | −139 | −141 |
| EBITDA | 205 | 134 | 107 | 78 | 28 |
| Depreciation & amort. | −5 | −4 | −17 | −13 | −19 |
| EBIT | 201 | 130 | 90 | 65 | 9 |
| Net financials | 36 | 16 | −6 | −0 | 24 |
| Profit before tax | 237 | 146 | 85 | 65 | 34 |
| Tax | 42 | 29 | 21 | 16 | 5 |
| Net profit | 195 | 116 | 64 | 49 | 28 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 887 | 930 | 915 | 884 | 844 |
| Equity | 866 | 915 | 905 | 880 | 835 |
| Long-term debt | 2 | 2 | — | 0 | 0 |
| Short-term debt | 19 | 12 | 10 | 4 | 10 |
| Total debt | 21 | 14 | 10 | 4 | 10 |
EBITDA margin
8.6%
This company
15.8%
Market median
-46% vs market
20202024
Equity ratio
98.8%
This company
38.2%
Market median
+159% vs market
20202024
Return on equity
3.4%
This company
18.4%
Market median
-82% vs market
20202024
Net profit margin
8.6%
This company
8.1%
Market median
+6% vs market
20202024
Asset turnover
0.39×
This company
1.12×
Market median
-65% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TK Chief Executive Officer | Chief Executive Officer | 2008 |
JA | Audit | 2025 |
KK Deputy auditor | Deputy auditor | 2025 |
| Former (1) | ||
NP | Audit | 2017 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2015 | |
| Board of Directors | 2015 | |
| Chairperson | 2015 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Implantbionics Ab also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Teija Kristina Lindholm | Chief Executive Officer | 0 companies |
| Jose Adam Juhani Kautonen | Audit | 0 companies |
| Niina Pauliina Lettojärvi | Audit | 0 companies |
| Kiri Kasperi Sopanen | Deputy auditor | 0 companies |
| Mark Andrew Lindholm | Board of Directors | 0 companies |
| Kevin Alec Lindholm | Board of Directors | 0 companies |
| Tom Christian Lindholm | Chairperson | 0 companies |